tirzepatide the best selling medication F.D.A. Approves New Obesity Drug That Will Compete With Wegovy Tirzepatide Crowns a New Global

doi: 10.1086/317647 253 PriniskiL

The engineered drug localized to lipid-rich plaque regions and CD11b/CD11c inflammatory cells, effectively suppressing inflammatory responses and enhancing cholesterol efflux ( By promoting cholesterol efflux and reducing foam-cell content within plaques, GLP-1RA therapy may decrease lipid core size and necrotic burden, thereby stabilizing the fibrous cap, lowering the risk of plaque rupture, and potentially reducing acute coronary events

When to Contact Your Clinical Team About Persistent Symptoms While most semaglutide side effects resolve within 24 weeks, some symptoms warrant clinical attention

McCann states